AU2021329999A1 - Use of fenretinide or an analogue thereof to treat pulmonary fibrosis - Google Patents

Use of fenretinide or an analogue thereof to treat pulmonary fibrosis Download PDF

Info

Publication number
AU2021329999A1
AU2021329999A1 AU2021329999A AU2021329999A AU2021329999A1 AU 2021329999 A1 AU2021329999 A1 AU 2021329999A1 AU 2021329999 A AU2021329999 A AU 2021329999A AU 2021329999 A AU2021329999 A AU 2021329999A AU 2021329999 A1 AU2021329999 A1 AU 2021329999A1
Authority
AU
Australia
Prior art keywords
fenretinide
analog
pharmaceutically acceptable
acceptable salt
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2021329999A
Other languages
English (en)
Inventor
Irenej Kianicka
Radu PISLARIU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laurent Pharmaceuticals Inc
Original Assignee
Laurent Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laurent Pharmaceuticals Inc filed Critical Laurent Pharmaceuticals Inc
Publication of AU2021329999A1 publication Critical patent/AU2021329999A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2021329999A 2020-08-25 2021-08-19 Use of fenretinide or an analogue thereof to treat pulmonary fibrosis Abandoned AU2021329999A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063069881P 2020-08-25 2020-08-25
US63/069,881 2020-08-25
PCT/CA2021/051148 WO2022040782A1 (en) 2020-08-25 2021-08-19 Use of fenretinide or an analogue thereof to treat pulmonary fibrosis

Publications (1)

Publication Number Publication Date
AU2021329999A1 true AU2021329999A1 (en) 2023-03-23

Family

ID=80352354

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021329999A Abandoned AU2021329999A1 (en) 2020-08-25 2021-08-19 Use of fenretinide or an analogue thereof to treat pulmonary fibrosis

Country Status (10)

Country Link
US (1) US20230310352A1 (https=)
EP (1) EP4203931A4 (https=)
JP (1) JP2023539847A (https=)
KR (1) KR20230079054A (https=)
CN (1) CN116437904A (https=)
AU (1) AU2021329999A1 (https=)
BR (1) BR112023003481A2 (https=)
CA (1) CA3128648A1 (https=)
MX (1) MX2023002347A (https=)
WO (1) WO2022040782A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250142485A (ko) 2024-03-22 2025-09-30 경희대학교 산학협력단 폐섬유증 예방 또는 치료용 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011127164A2 (en) * 2010-04-08 2011-10-13 Fate Therapeutics, Inc. Pharmaceutical compositions to treat fibrosis
TWI658830B (zh) * 2011-06-08 2019-05-11 日東電工股份有限公司 Ｈｓｐ47表現調控強化用類視色素脂質體
US10406127B2 (en) * 2014-07-25 2019-09-10 Laurent Pharmaceuticals Solid oral formulation of fenretinide

Also Published As

Publication number Publication date
BR112023003481A2 (pt) 2023-05-09
WO2022040782A1 (en) 2022-03-03
EP4203931A4 (en) 2024-11-13
JP2023539847A (ja) 2023-09-20
KR20230079054A (ko) 2023-06-05
EP4203931A1 (en) 2023-07-05
MX2023002347A (es) 2023-04-20
CN116437904A (zh) 2023-07-14
US20230310352A1 (en) 2023-10-05
CA3128648A1 (en) 2022-02-25

Similar Documents

Publication Publication Date Title
US20170319548A1 (en) Cenicriviroc combination therapy for the treatment of fibrosis
JP2014520842A (ja) モンテルカストおよびリボセチリジン配合のカプセル製剤
US10398713B2 (en) Compositions and methods for the treatment of neurodegenerative and other diseases
US20140275237A1 (en) Beraprost isomer as an agent for the treatment of viral infection
JP6163165B2 (ja) レボセチリジンまたはその医薬的に許容される塩およびモンテルカストまたはその医薬的に許容される塩を含む経口投与用安定医薬製剤
US11833151B2 (en) Pharmaceutical composition including sodium alkyl sulfate
KR20170042504A (ko) 섬유성 질환의 치료에 사용하기 위한 ppar 화합물
CA2865380A1 (en) Solid pharmaceutical composition containing 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or salt thereof
US9907789B2 (en) Sustained-release preparation
US20120141586A1 (en) Thrombin receptor antagonist and clopidogrel fixed dose tablet
ZA200409237B (en) Immediate release pharmaceutical formulation.
US20230310352A1 (en) Novel compositions and methods for the treatment of lung fibrosis
JP6088429B2 (ja) 関節リウマチなどの自己免疫疾患の治療の改善方法
US20250360181A1 (en) Use of cyclosporine analogues for treating fibrosis
US12496293B2 (en) Solid pharmaceutical preparation
JP4045301B2 (ja) 肺胞破壊によって生じる肺疾患の治療または予防のためのクラリスロマイシンまたはその塩
KR20230097100A (ko) 테트라하이드로칸나비놀 및 이를 포함하는 조성물을 사용한 급성 호흡 부전 및/또는 급성 호흡 곤란 증후군을 치료하기 위한 조성물 및 방법
JP2021522177A (ja) イオン輸送体の活性を増強するための組成物および方法ならびにその使用
AU2021242812A1 (en) Use of fenretinide for the treatment of SARS-corona virus infection
WO2022051318A1 (en) Fixed dose combinations of chs-131 and a thyroid receptor beta agonist
CN111481544A (zh) 药物制剂
WO2017062611A1 (en) Methods for the treatment of cystic fibrosis
HK1200337B (en) Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period